RESEARCHER PROFILE

Peter Johnson

← Back to University of Southampton

P

University of Southampton

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchReproductive System and PregnancyViral-associated cancers and disordersT-cell and B-cell Immunology

Peter Johnson works in Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Reproductive System and Pregnancy, Viral-associated cancers and disorders, T-cell and B-cell Immunology. Recorded institutional associations include Cancer Research UK, University Hospital Southampton NHS Foundation Trust, NIHR CRUK Experimental Cancer Medicine Centre.

872Publications
37,399Citations
96H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    2013 · 1,682 citations
  2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    2015 · 930 citations
  3. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

    1998 · 893 citations
  4. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

    2016 · 818 citations
  5. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

    2015 · 762 citations
  6. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

    2016 · 615 citations
  7. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    2019 · 608 citations
  8. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

    2013 · 561 citations
  9. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

    1993 · 543 citations
  10. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study

    2020 · 539 citations
  11. European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

    2000 · 472 citations
  12. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

    2015 · 410 citations
  13. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    2017 · 391 citations
  14. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

    2003 · 390 citations
  15. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

    2019 · 353 citations
  16. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    2020 · 350 citations
  17. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

    2010 · 348 citations
  18. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.

    1995 · 337 citations
  19. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

    2021 · 337 citations
  20. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

    2010 · 335 citations
  21. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study

    2021 · 308 citations
  22. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

    2018 · 300 citations
  23. Clinical trials of antibody therapy

    2000 · 288 citations
  24. Mechanism of action of rituximab

    2002 · 287 citations
  25. Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling

    2008 · 284 citations

← Return to the university profile